RBR-36x4c4d进行中（未招募）1 期
Cannabidiol as a therapy for spinocerebellar ataxia
niversidade Federal do Paraná0 个研究点开始时间: 2023年7月11日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18Y 至 0（—）
入选标准
- •Patients from the Movement Disorders Outpatient Clinic of the Neurology Service of the Hospital de Clínicas - UFPR (HC - UFPR) over 18 years old who already had the genetic diagnosis of spinocerebellar ataxia type 10 (SCA10); patients who agreed and signed the Informed Consent Form.
排除标准
- •Patients who did not agree with the Informed Consent Form; patients who did not have a genetic diagnosis of SCA10; demented patients; and patients who did not use the intervention correctly.
研究者
相似试验
终止
2 期
Cannabidiol: Treatment for brain changes and depression in early-stage dementiaEarly-stage dementiaNeurological - DementiasACTRN12621001364864niversity of Wollongong1
进行中（未招募）
1 期
MEDICAL CANNABIS TREATMENT IN NEURODEGENERATIVE DISEASES (NEUROBIS)Patients suffering from neurodegenerative diseases: Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s Disease (AD) and Parkinson’s Disease (PD).CTIS2023-507715-35-02Azienda Ospedaliero-Universitaria Maggiore Della Carita186
进行中（未招募）
1 期
Cannabidiol as an add-on therapy in treatment-refractory psychotic disordersMedDRA version: 16.1Level: HLGTClassification code 10039628Term: Schizophrenia and other psychotic disordersSystem Organ Class: 10037175 - Psychiatric disordersSchizophreniaEUCTR2013-000240-26-GBKing's College London
进行中（未招募）
2 期
Multi-centre trial of cannabidiol (CBD) for the treatment of Parkinson's disease psychosisISRCTN87895237King’s College London and South London & Maudsley NHS Foundation Trust144
招募中
3 期
Cannabidiol for treatment of non-affective psychosis and cannabis use2024-517630-18-00Region Hovedstaden64